Back to top
more

Cytek Biosciences (CTKB)

(Delayed Data from NSDQ)

$3.88 USD

3.88
1,107,853

+0.04 (1.04%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Encompass Health (EHC) Up 32% in 6 Months: More Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing facility count within its Inpatient Rehabilitation segment and sound liquidity position.

Zacks Equity Research

Here's Why Cytek Biosciences, Inc. (CTKB) is Poised for a Turnaround After Losing -16.6% in 4 Weeks

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Here's Why You Should Retain HCA Healthcare (HCA) Stock Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek

by Zacks Equity Research

Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek.

Shrabana Mukherjee headshot

4 Top Stocks for Higher Returns on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Genesco (GCO), Hertz (HTZ), Suburban (SPH) and Cytek (CTKB).

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.